The role of indapamide in therapy of hypertension Review article
Article Sidebar
Published:
Mar 31, 2016
Keywords:
indapamide, hypertension, cardiovascular risk
Main Article Content
Abstract
Treatment of hypertension is fundamental for the prevention of cardiovascular events and mortality. Thiazide-like diuretics are a class of drugs commonly recommended as first‐line treatment for raised blood pressure due to their influence on reduction of death, stroke and heart attacks. Indapamide is a long-acting thiazide-like diuretic that lowers blood pressure either through its natriuretic diuretic effect and long-term antihypertensive efficacy caused calcium antagonist-like vasorelaxant activities. The favorable effects of indapamide extend across of protecting effects in a variety of conditions associated with high cardiovascular risk, such as diabetes, left ventricular hypertrophy, nephropathy and stroke. Recent multicentre clinical trials have shown that indapamide is well tolerated and has the advantage of having no adverse impact on glucose and lipid metabolism as well as it is highly effective in lowering blood pressure, whether given alone or in combination.
Article Details
How to Cite
Wyleżoł, P., Solarska, M., Pordzik, J., & Postuła , M. (2016). The role of indapamide in therapy of hypertension. Medycyna Faktow (J EBM), 9(1(30), 55-61. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2271
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension. J. Hypertens. 2013; 31: 1281-1357.
3. Barrios V., Escobar C.: Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility. Integr. Blood Press. Control 2010; 3: 11-19.
4. Schiavi P., Jochemsen R., Guez D.: Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam. Clin. Pharmacol. 2000; 14(2): 139-146.
5. Robinson D.M., Wellington K.: Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs 2006; 66(2): 257-271.
6. Burk T.J., Nobles E.M., Wolf P.S. et al.: Effect of indapamide on volume-dependent hypertension, renal hemodynamics, solute excretion and proximal nephron fractional reabsorption in the dog. Curr. Med. Res. Opin. 1983; 8(3): 25-34.
7. Finch L., Hicks P.E., Oheim K. et al.: The effects of indapamide on vascular reactivity in hypertension. Curr. Med. Res. Opin. 1977; 5(1): 44-54.
8. Mironneau J., Savineau J.P., Mironneau C.: Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. Eur. J. Pharmacol. 1981; 75: 109-113.
9. Uehara Y., Shirahase H., Naga T. et al.: Radical scavengers of indapamide in prostacyclin synthesis in rat smooth muscle cell. Hypertension 1990; 15: 216-224.
10. Pawlaczyk-Gabriel K., Niklas A., Uruski P., Tykarski A.: Miejsce indapamidu o przedłużonym uwalnianiu w terapii nadciśnienia tętniczego. Nadciśnienie Tętnicze 2014; 18(4): 211-223.
11. Franklin S.S., Gustin W., Wong N.D. et al.: Haemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
12. London G., Schmieder R., Calvo C. et al.: Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am. J. Hypertens. 2006; 19(1): 113-121.
13. Emeriau J.P., Knauf H., Pujadas J.O. et al.; European Study Investigators: A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J. Hypertens. 2001; 19(2): 343-350.
14. Piotrowski W., Włodarczyk P., Jasiński B. et al.: Ocena skuteczności i tolerancji indapamidu o powolnym uwalnianiu w dawce 1,5 mg u chorych powyżej 55. r.ż. z izolowanym nadciśnieniem skurczowym. Badanie STIP – 12-tygodniowe otwarte badanie wieloośrodkowe. Nadciśnienie Tętnicze 2001; 5(4): 245-254.
15. Błędowski P., Mossakowska M., Chudek J. et al.: Medical, psychological and socioeconomic aspects of aging in Poland. Assumptions and objectives of the PolSenior project. Exp. Gerontol. 2011; 46(12): 1003-1009.
16. Beckett N.S., Peters R., Fletcher A.E. et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-1898.
17. Witkowska M.: Izolowane nadciśnienie tętnicze – niezależny czynnik zagrożenia powikłaniami sercowo-naczyniowymi. Nadciśnienie Tętnicze 2000; 4(3): 201-207.
18. PATS Collaborating Group: Post-Stroke Antihypertensive Treatment Study: a preliminary result. Chin. Med. J. 1995; 108: 710-717.
19. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
20. Marre M., Puig J.G., Kokot F. et al.: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004; 22(8): 1613-1622.
21. Patel A., MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840.
22. Zoungas S., Chalmers J., Neal B. et al.: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
23. Gosse P., Sheridan D.J., Zannad F. et al.: Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs enalapril 20 mg: the LIVE study. J. Hypertens. 2000; 18: 1465-1475.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension. J. Hypertens. 2013; 31: 1281-1357.
3. Barrios V., Escobar C.: Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility. Integr. Blood Press. Control 2010; 3: 11-19.
4. Schiavi P., Jochemsen R., Guez D.: Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam. Clin. Pharmacol. 2000; 14(2): 139-146.
5. Robinson D.M., Wellington K.: Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs 2006; 66(2): 257-271.
6. Burk T.J., Nobles E.M., Wolf P.S. et al.: Effect of indapamide on volume-dependent hypertension, renal hemodynamics, solute excretion and proximal nephron fractional reabsorption in the dog. Curr. Med. Res. Opin. 1983; 8(3): 25-34.
7. Finch L., Hicks P.E., Oheim K. et al.: The effects of indapamide on vascular reactivity in hypertension. Curr. Med. Res. Opin. 1977; 5(1): 44-54.
8. Mironneau J., Savineau J.P., Mironneau C.: Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. Eur. J. Pharmacol. 1981; 75: 109-113.
9. Uehara Y., Shirahase H., Naga T. et al.: Radical scavengers of indapamide in prostacyclin synthesis in rat smooth muscle cell. Hypertension 1990; 15: 216-224.
10. Pawlaczyk-Gabriel K., Niklas A., Uruski P., Tykarski A.: Miejsce indapamidu o przedłużonym uwalnianiu w terapii nadciśnienia tętniczego. Nadciśnienie Tętnicze 2014; 18(4): 211-223.
11. Franklin S.S., Gustin W., Wong N.D. et al.: Haemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
12. London G., Schmieder R., Calvo C. et al.: Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am. J. Hypertens. 2006; 19(1): 113-121.
13. Emeriau J.P., Knauf H., Pujadas J.O. et al.; European Study Investigators: A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J. Hypertens. 2001; 19(2): 343-350.
14. Piotrowski W., Włodarczyk P., Jasiński B. et al.: Ocena skuteczności i tolerancji indapamidu o powolnym uwalnianiu w dawce 1,5 mg u chorych powyżej 55. r.ż. z izolowanym nadciśnieniem skurczowym. Badanie STIP – 12-tygodniowe otwarte badanie wieloośrodkowe. Nadciśnienie Tętnicze 2001; 5(4): 245-254.
15. Błędowski P., Mossakowska M., Chudek J. et al.: Medical, psychological and socioeconomic aspects of aging in Poland. Assumptions and objectives of the PolSenior project. Exp. Gerontol. 2011; 46(12): 1003-1009.
16. Beckett N.S., Peters R., Fletcher A.E. et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-1898.
17. Witkowska M.: Izolowane nadciśnienie tętnicze – niezależny czynnik zagrożenia powikłaniami sercowo-naczyniowymi. Nadciśnienie Tętnicze 2000; 4(3): 201-207.
18. PATS Collaborating Group: Post-Stroke Antihypertensive Treatment Study: a preliminary result. Chin. Med. J. 1995; 108: 710-717.
19. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041.
20. Marre M., Puig J.G., Kokot F. et al.: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004; 22(8): 1613-1622.
21. Patel A., MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-840.
22. Zoungas S., Chalmers J., Neal B. et al.: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
23. Gosse P., Sheridan D.J., Zannad F. et al.: Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs enalapril 20 mg: the LIVE study. J. Hypertens. 2000; 18: 1465-1475.